Toronto Digestive Disease Associates, Inc.

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Crohn's disease3 trials
• Ulcerative colitis2 trials

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Alfasigma S.p.A.1 trial
• Janssen Research & Development, LLC1 trial
• Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 trial
• Takeda1 trial

Running trials

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

  Contact: David Ford (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting

Closed trials

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source